3 Things That Matter Most for Eli Lilly Now

Eli Lilly’s Q2 2026 revenue was heavily driven by GLP-1 drugs, with Mounjaro up 91% YoY, Zepbound up 46% YoY, and the newly launched Foundayo pill starting to contribute—together nearly $15B out of ~$23B total revenue (about two-thirds). The article flags a potential GLP-1 growth slowdown (Zepbound growth already decelerated from 172% in Q2 2025 to 46% in Q2 2026) and warns that reliance on a single drug class remains a concentration risk. It also notes management is using GLP-1 cash to fund acquisitions in new treatment areas, but stresses that development timelines and candidate failure risk could limit longer-term payoff.

Analysis

The real issue is not near-term earnings power; it is whether the market is still willing to pay a category-monopoly multiple once the growth curve normalizes. A business that is already a major share of revenue concentration starts to behave more like a duration asset than a simple compounder: small changes in prescription momentum, payer behavior, or patent-life confidence can drive outsized multiple compression before the P&L actually rolls over. That makes the stock vulnerable over the next 1-3 quarters if weekly script data, refill rates, or gross-to-net trends soften, even modestly.

The second-order effect is that GLP-1s are increasingly a managed-benefit category, which shifts bargaining power toward PBMs and large employers. That tends to cap pricing power across the whole obesity/diabetes franchise and can turn current upside into a rebate arms race, especially if supply normalizes and competitor launches become more credible. Over 6-18 months, the key question is whether acquisition spending can truly diversify the story fast enough; if not, the market may start to value LLY less like a platform and more like a mature pharma with one dominant asset class.

Contrarian view: consensus is focused on the size of the opportunity, but the more important variable may be the deceleration rate. If the market is already underwriting perfection, the first sign of share loss, pricing concessions, or slower new-patient adds could matter more than another strong revenue print. The thesis is falsified if oral GLP-1 adoption materially expands the addressable market without meaningful price erosion, or if non-obesity pipeline assets begin to contribute visible upside within the next two earnings cycles.

Key Decisions for Investors

• Do not chase LLY strength after a positive headline; if entering short exposure, wait for a post-earnings or sector-rally extension and use a 1-3 month put spread to define risk. Falsify on accelerating script growth or raised full-year guidance.
• Pair trade: short LLY / long NVO on any evidence of U.S. prescription growth deceleration. The setup is a multiple-normalization trade, not a franchise-destruction call; cover if LLY retains premium growth vs. peers for two consecutive quarters.
• Watch PBM and payer commentary closely over the next 1-2 quarters; if rebate pressure rises, consider reducing any LLY long-only exposure because margin surprise will likely turn negative before revenue does.
• If you want a lower-conviction expression, prefer a small bearish call spread in LLY over outright short stock. The payoff is better if the market re-rates the name, but risk is capped if the obesity category continues to expand.